Literature DB >> 25920320

Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole.

Brittany B Lewis1, Charlie G Buffie1, Rebecca A Carter2, Ingrid Leiner2, Nora C Toussaint3, Liza C Miller4, Asia Gobourne4, Lilan Ling4, Eric G Pamer5.   

Abstract

Antibiotic administration disrupts the intestinal microbiota, increasing susceptibility to pathogens such as Clostridium difficile. Metronidazole or oral vancomycin can cure C. difficile infection, and administration of these agents to prevent C. difficile infection in high-risk patients, although not sanctioned by Infectious Disease Society of America guidelines, has been considered. The relative impacts of metronidazole and vancomycin on the intestinal microbiota and colonization resistance are unknown. We investigated the effect of brief treatment with metronidazole and/or oral vancomycin on susceptibility to C. difficile, vancomycin-resistant Enterococcus, carbapenem-resistant Klebsiella pneumoniae, and Escherichia coli infection in mice. Although metronidazole resulted in transient loss of colonization resistance, oral vancomycin markedly disrupted the microbiota, leading to prolonged loss of colonization resistance to C. difficile infection and dense colonization by vancomycin-resistant Enterococcus, K. pneumoniae, and E. coli. Our results demonstrate that vancomycin, and to a lesser extent metronidazole, are associated with marked intestinal microbiota destruction and greater risk of colonization by nosocomial pathogens.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Clostridium difficile; colonization resistance; metronidazole; microbiota; vancomycin

Mesh:

Substances:

Year:  2015        PMID: 25920320      PMCID: PMC4621244          DOI: 10.1093/infdis/jiv256

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection.

Authors:  Sandra Rodriguez; Marlow B Hernandez; Giorgio Tarchini; Megan Zaleski; Marjon Vatanchi; Lyssette Cardona; Fernando Castro-Pavia; Alison Schneider
Journal:  Clin Gastroenterol Hepatol       Date:  2014-03-27       Impact factor: 11.382

2.  Appropriateness of empiric therapy in patients with suspected Clostridium difficile infection.

Authors:  Elie Saade; Abhishek Deshpande; Sirisha Kundrapu; Venkata C K Sunkesula; Dubert M Guerrero; Lucy A Jury; Curtis J Donskey
Journal:  Curr Med Res Opin       Date:  2013-06-05       Impact factor: 2.580

Review 3.  Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists.

Authors:  Robert C Owens
Journal:  Pharmacotherapy       Date:  2006-03       Impact factor: 4.705

4.  Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.

Authors:  Cirle A Warren; Edward J van Opstal; Mary S Riggins; Yuesheng Li; John H Moore; Glynis L Kolling; Richard L Guerrant; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

5.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Authors:  Stuart Johnson; Thomas J Louie; Dale N Gerding; Oliver A Cornely; Scott Chasan-Taber; David Fitts; Steven P Gelone; Colin Broom; David M Davidson
Journal:  Clin Infect Dis       Date:  2014-05-05       Impact factor: 9.079

Review 6.  Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis.

Authors:  Claudia Slimings; Thomas V Riley
Journal:  J Antimicrob Chemother       Date:  2013-12-08       Impact factor: 5.790

7.  Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.

Authors:  Christine M Bassis; Casey M Theriot; Vincent B Young
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

8.  Emergence and global spread of epidemic healthcare-associated Clostridium difficile.

Authors:  Miao He; Fabio Miyajima; Paul Roberts; Louise Ellison; Derek J Pickard; Melissa J Martin; Thomas R Connor; Simon R Harris; Derek Fairley; Kathleen B Bamford; Stephanie D'Arc; Jon Brazier; Derek Brown; John E Coia; Gill Douce; Dale Gerding; Hee Jung Kim; Tse Hsien Koh; Haru Kato; Mitsutoshi Senoh; Tom Louie; Stephen Michell; Emma Butt; Sharon J Peacock; Nick M Brown; Tom Riley; Glen Songer; Mark Wilcox; Munir Pirmohamed; Ed Kuijper; Peter Hawkey; Brendan W Wren; Gordon Dougan; Julian Parkhill; Trevor D Lawley
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330

9.  Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.

Authors:  Turki Abujamel; Jennifer L Cadnum; Lucy A Jury; Venkata C K Sunkesula; Sirisha Kundrapu; Robin L Jump; Alain C Stintzi; Curtis J Donskey
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

10.  Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.

Authors:  David W Eyre; Farah Babakhani; David Griffiths; Jaime Seddon; Carlos Del Ojo Elias; Sherwood L Gorbach; Tim E A Peto; Derrick W Crook; A Sarah Walker
Journal:  J Infect Dis       Date:  2013-11-11       Impact factor: 5.226

View more
  69 in total

Review 1.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

2.  Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection.

Authors:  Michael C Abt; Brittany B Lewis; Silvia Caballero; Huizhong Xiong; Rebecca A Carter; Bože Sušac; Lilan Ling; Ingrid Leiner; Eric G Pamer
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

3.  Point-Counterpoint: What Is the Optimal Approach for Detection of Clostridium difficile Infection?

Authors:  Ferric C Fang; Christopher R Polage; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2017-01-11       Impact factor: 5.948

4.  Clinical heterogeneity of patients with stool samples testing PCR+/Tox- from a two-step Clostridium difficile diagnostic algorithm.

Authors:  Jason Zou; Victor Leung; Sylvie Champagne; Michelle Hinch; Anna Wong; Elisa Lloyd-Smith; Trong Tien Nguyen; Marc G Romney; Azra Sharma; Michael Payne; Christopher F Lowe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-20       Impact factor: 3.267

5.  Initial Gut Microbial Composition as a Key Factor Driving Host Response to Antibiotic Treatment, as Exemplified by the Presence or Absence of Commensal Escherichia coli.

Authors:  Tingting Ju; Yasmeen Shoblak; Yanhua Gao; Kaiyuan Yang; Janelle Fouhse; B Brett Finlay; Yee Wing So; Paul Stothard; Benjamin P Willing
Journal:  Appl Environ Microbiol       Date:  2017-08-17       Impact factor: 4.792

6.  Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.

Authors:  David M Faleck; Hojjat Salmasian; E Yoko Furuya; Elaine L Larson; Julian A Abrams; Daniel E Freedberg
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

Review 7.  Clostridium difficile colitis: pathogenesis and host defence.

Authors:  Michael C Abt; Peter T McKenney; Eric G Pamer
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

8.  Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Authors:  Peter Warn; Pia Thommes; Abdul Sattar; David Corbett; Amy Flattery; Zuo Zhang; Todd Black; Lorraine D Hernandez; Alex G Therien
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 9.  The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens.

Authors:  Sohn Kim; April Covington; Eric G Pamer
Journal:  Immunol Rev       Date:  2017-09       Impact factor: 12.988

10.  Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.

Authors:  Abhishek Deshpande; Kelly Hurless; Jennifer L Cadnum; Laurent Chesnel; Lihong Gao; Luisa Chan; Sirisha Kundrapu; Alexander Polinkovsky; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.